Payment overview · 2025
General Payments
$240.30
13 reported records · 6 companies
Healthcare provider profile · identity verified
Joanne Combs
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BOONEVILLE, KY · NPI 1932652096
Verified facts
What the public records show
CMS Open Payments records show Joanne Combs received $240.30 in general payments during 2025 across 13 reported records.
Indivior Inc. accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $68.19 | 28.4% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $51.53 | 21.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.15 | 20.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.12 | 17.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.11 | 6.7% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $14.20 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.30 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $68.19 | 4 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $51.53 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.12 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 405 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 341 | 49 |
| Gabapentin | Gabapentin | 315 | 55 |
| Omeprazole | Omeprazole | 179 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 174 | 35 |
| Metformin Hcl | Metformin Hcl | 144 | 33 |
| Lisinopril | Lisinopril | 143 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 85 | 24 |
| Famotidine | Famotidine | 81 | 20 |
| Prednisone | Prednisone | 79 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 78 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 19 |
| Glipizide | Glipizide | 72 | 13 |
| Ibuprofen | Ibuprofen | 72 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 67 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 19 |
| Furosemide | Furosemide | 62 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 13 |
| Fluconazole | Fluconazole | 57 | 22 |
| Promethazine Hcl | Promethazine Hcl | 57 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 17 |
| Linzess | Linaclotide | 51 | 19 |
| Amoxicillin | Amoxicillin | 50 | 38 |
| Farxiga | Dapagliflozin Propanediol | 50 | 12 |
| Buprenorphine Hcl | Buprenorphine Hcl | 49 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 49 | 19 |
| Simvastatin | Simvastatin | 48 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 13 |
| Meloxicam | Meloxicam | 45 | 12 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 39 | 12 |
| Potassium Chloride | Potassium Chloride | 38 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Losartan Potassium | Losartan Potassium | 35 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | 12 |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ibu | Ibuprofen | 18 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Atenolol | Atenolol | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.30 · 13 records | Indivior Inc. | BRIXADI, CAPLYTA, ELIQUIS, LYBALVI, NURTEC ODT, QULIPTA, SUBLOCADE, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error